Jade Biosciences, Inc. is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel peptide-based therapeutics for patients suffering from inflammatory and immune-mediated diseases. Leveraging proprietary endogenous peptides originally identified in amphibian defense systems, the company’s research platform focuses on modulating key signaling pathways in chronic conditions that currently lack safe and effective treatments. Headquartered in North Carolina, Jade Biosciences conducts preclinical and clinical work in the United States and collaborates with regulatory and research partners worldwide to advance its pipeline.
The company’s lead asset, JBI-1001, is undergoing clinical evaluation as a potential first-in-class topical treatment for bullous pemphigoid, a rare autoimmune blistering disorder affecting elderly patients. In addition, Jade’s pipeline includes JBI-1101, which is being explored for chronic ocular surface diseases, and JBI-2001, targeting inflammatory bowel conditions. Each peptide candidate is designed for localized delivery with the goal of reducing systemic exposure and improving patient tolerability.
Since its founding in 2019, Jade Biosciences has grown its multidisciplinary team of immunologists, peptide chemists and clinical development experts. The company’s management team is led by Chief Executive Officer Dr. Michael Brazis, who has over two decades of experience in biotech R&D, and Chief Scientific Officer Dr. Arnold Lee, a recognized authority on peptide therapeutics. Jade maintains partnerships with leading academic institutions, including the University of North Carolina and Mayo Clinic, to leverage translational science in support of its clinical programs.
Jade Biosciences serves patient communities and healthcare providers across North America, Europe and Asia through its clinical trial networks and strategic alliances. By advancing innovative peptide modalities into later-stage development, the company aims to address significant unmet medical needs in dermatology, ophthalmology and gastroenterology, positioning itself for potential commercialization and broader global impact.
AI Generated. May Contain Errors.
Free JBIO Stock Alerts